knowledge -WSS

knowledge

author：fashion 2025-10-01 14:40:21 - browse：4149

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： As obesity drug market grows, telehealth companies court payers

WSS

European regulators consider appeal over Amylyx ALS drug

What the Wegovy shortage looks like for doctors — and for patients

Vivek Ramaswamy made waves in the debate, much as in biotech

Humana CEO Bruce Broussard to step down in 2024

A revolution in caring for preterm infants

Wellcome Trust names Røttingen as its new CEO

entertainment

knowledge

focus

Wildfire smoke exposes gaps in outdoor worker protections

How to make over

State Dept. review finds Biden bears some blame for Afghanistan failures

How the drug

Virginia high school admissions case could be legal follow

People can get long Covid without testing positive for virus: Study

Medicare details structure of new drug price negotiation program

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Duchenne breakthrough therapy leaves behind pioneering families

As obesity drug market grows, telehealth companies court payers

hotspot

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

A revolution in caring for preterm infants

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

How clinical AI models' predictive power can degrade over time

Akero's treatment for NASH falls short in cirrhosis study

How doctors and nurses shape Google's AI

hotspot

entertainment

hotspot

knowledge